How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study

Table 2 Comparison of composition of drugs for treatment and disease states according to colonoscopy findings 2 and 5 yr after diagnosis before (group A) and after (group B) infliximab approval

	Group A (n = 48)	Group B (n = 62)	P value
Maintenance treatment 2 year after diagnosis
None	0	5 (8.1)	0.045
5-Aminosalicylate	47 (97.9)	46 (74.2)	0.001
Azathioprine	43 (89.6)	36 (58.1)	0.001
Infliximab	0	34 (54.8)	< 0.001
Adalimumab	0	0
Vedolizumab	0	0
Ustekinumab	0	0
Tofacitinib	0	0
Disease extent of Paris classification 2 years after diagnosis			0.012b
Remission	14 (29.2)	31 (50.0)
E1 proctitis	13 (27.1)	11 (17.7)
E2 left colitis	2 (4.2)	8 (12.9)
E3 right colitis	6 (12.5)	8 (12.9)
E4 pancolitis	13 (27.1)	4 (6.5)
Mayo endoscopic subscore 2 years after diagnosisa			0.037b
0 normal or inactive	15 (24.2)	33 (53.2)
1 mild	24 (50.0)	21 (33.9)
2 moderate	8 (16.7)	8 (12.9)
3 severe	1 (2.1)	0
	Group A (n = 24)	Group B (n = 31)	P value
Maintenance treatment 5 year after diagnosis
None	2 (8.3)	5 (16.1)	0.394
5-aminosalicylate	21 (87.5)	15 (48.4)	0.003
Azathioprine	14 (58.3)	14 (45.2)	0.337
Infliximab	0	18 (58.1)	< 0.001
Adalimumab	0	2 (6.5)
Vedolizumab	0	1 (3.2)
Ustekinumab	0	0
Tofacitinib	0	0
Disease extent of Paris classification 5 years after diagnosis			0.016b
Remission	3 (12.5)	13 (41.9)
E1 proctitis	9 (37.5)	9 (29.0)
E2 left colitis	3 (12.5)	4 (12.9)
E3 right colitis	2 (8.3)	2 (6.5)
E4 pancolitis	7 (29.2)	3 (9.7)
Mayo endoscopic subscore 5 years after diagnosisa			< 0.001b
0 normal or inactive	3 (12.5)	13 (41.9)
1 mild	6 (25.0)	16 (51.6)
2 moderate	14 (58.3)	2 (6.5)
3 severe	1 (4.2)	0

^aMayo endoscopy subscores were as follows: 0: Normal or inactive disease; 1: Mild disease; 2: Moderate disease; and 3: Severe disease.

^bMann-Whitney test.

Values are n (percentage).